BioMarin Pharmaceutical Inc. presented data at The Endocrine Society Annual Meeting, ENDO 2022, demonstrating the Company's ongoing commitment to understanding the lifetime impact of...
BioMarin Pharmaceutical Inc. announced that the Company presented positive results from a two-year analysis of the Phase 3 GENEr8-1 study and an overall safety...
BioMarin Pharmaceutical Inc. announced that the Company will be presenting data in several presentations on valoctocogene roxaparvovec, an investigational gene therapy for the treatment...
